## Lee Yong Lim

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5892489/publications.pdf

Version: 2024-02-01

110	8,708	44	91
papers	citations	h-index	g-index
110	110	110	11937 citing authors
all docs	docs citations	times ranked	

#	Article	IF	CITATIONS
1	Critical material designs for mucus- and mucosa-penetrating oral insulin nanoparticle development. International Materials Reviews, 2023, 68, 121-139.	9.4	11
2	Prescribing in a pediatric hospital setting – Lost in translation?. Patient Education and Counseling, 2022, 105, 1614-1619.	1.0	1
3	A randomised controlled trial of a novel tramadol chewable tablet: pharmacokinetics and tolerability in children. Anaesthesia, 2022, , .	1.8	1
4	An investigation of the suitability of melissopalynology to authenticate Jarrah honey. Current Research in Food Science, 2022, 5, 506-514.	2.7	9
5	Australian Honeypot Ant (Camponotus inflatus) Honey—A Comprehensive Analysis of the Physiochemical Characteristics, Bioactivity, and HPTLC Profile of a Traditional Indigenous Australian Food. Molecules, 2022, 27, 2154.	1.7	1
6	A Comprehensive Survey of Phenolic Constituents Reported in Monofloral Honeys around the Globe. Foods, 2022, 11, 1152.	1.9	13
7	Effects of Formulation on the Palatability and Efficacy of In-Feed Praziquantel Medications for Marine Finfish Aquaculture. Marine Drugs, 2022, 20, 323.	2.2	1
8	A Review of the Phytochemistry and Bioactivity of Clover Honeys (Trifolium spp.). Foods, 2022, 11, 1901.	1.9	8
9	Antioxidant HPTLC-DPPH Fingerprinting of Honeys and Tracking of Antioxidant Constituents upon Thermal Exposure. Foods, 2021, 10, 357.	1.9	12
10	Prior administration of chocolate improves the palatability of bitter drugs: The <scp>Chocâ€withâ€Med</scp> study. Journal of Paediatrics and Child Health, 2021, 57, 1267-1273.	0.4	5
11	Honey-Based Medicinal Formulations: A Critical Review. Applied Sciences (Switzerland), 2021, 11, 5159.	1.3	28
12	Development and validation of a high-performance thin-layer chromatography assay for the analysis of tacrolimus ointments. Journal of Planar Chromatography - Modern TLC, 2021, 34, 189-195.	0.6	1
13	Optimisation of Bee Pollen Extraction to Maximise Extractable Antioxidant Constituents. Antioxidants, 2021, 10, 1113.	2.2	20
14	Development of an HPTLC-based dynamic reference standard for the analysis of complex natural products using Jarrah honey as test sample. PLoS ONE, 2021, 16, e0254857.	1.1	8
15	Storage stability of chocolate-based CDS formulations of midazolam and tramadol as whole tablets, quarter sized tablets and as reconstituted aqueous liquids. Journal of Drug Delivery Science and Technology, 2021, 64, 102574.	1.4	3
16	Detection of syrup adulterants in manuka and jarrah honey using HPTLC-multivariate data analysis. PeerJ, 2021, 9, e12186.	0.9	4
17	Stabilisation of Recombinant Human Basic Fibroblast Growth Factor (FGF-2) against Stressors Encountered in Medicinal Product Processing and Evaluation. Pharmaceutics, 2021, 13, 1762.	2.0	8
18	HPLC-UV assay of tramadol and O-desmethyltramadol in human plasma containing other drugs potentially co-administered to participants in a paediatric population pharmacokinetic study. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2021, 1184, 122971.	1.2	8

#	Article	IF	CITATIONS
19	Parents' perspectives towards paediatric confectionary masked medications: a qualitative study. International Journal of Clinical Pharmacy, 2021, , 1.	1.0	2
20	A validated method for the quantitative determination of sugars in honey using high-performance thin-layer chromatography. Journal of Planar Chromatography - Modern TLC, 2020, 33, 489-499.	0.6	16
21	Sugar Profiling of Honeys for Authentication and Detection of Adulterants Using High-Performance Thin Layer Chromatography. Molecules, 2020, 25, 5289.	1.7	28
22	Fibroblast Growth Factor 2â€"A Review of Stabilisation Approaches for Clinical Applications. Pharmaceutics, 2020, 12, 508.	2.0	56
23	Development and validation of an HPTLC–DPPH assay and its application to the analysis of honey. Journal of Planar Chromatography - Modern TLC, 2020, 33, 301-311.	0.6	15
24	Metal ion-responsive nanocarrier derived from phosphonated calix[4]arenes for delivering dauricine specifically to sites of brain injury in a mouse model of intracerebral hemorrhage. Journal of Nanobiotechnology, 2020, 18, 61.	4.2	19
25	Targeting strategies for drug delivery to the kidney: From renal glomeruli to tubules. Medicinal Research Reviews, 2019, 39, 561-578.	5.0	63
26	Dual-responsive, Methotrexate-loaded, Ascorbic acid-derived Micelles Exert Anti-tumor and Anti-metastatic Effects by Inhibiting NF-κB Signaling in an Orthotopic Mouse Model of Human Choriocarcinoma. Theranostics, 2019, 9, 4354-4374.	4.6	17
27	Taste evaluation of a novel midazolam tablet for pediatric patients: In vitro drug dissolution, in vivo animal taste aversion and clinical taste perception profiles. International Journal of Pharmaceutics, 2018, 535, 194-200.	2.6	18
28	A novel, palatable paediatric oral formulation of midazolam: pharmacokinetics, tolerability, efficacy and safety. Anaesthesia, 2018, 73, 1469-1477.	1.8	21
29	Alginate–C18 Conjugate Nanoparticles Loaded in Tripolyphosphate-Cross-Linked Chitosan–Oleic Acid Conjugate-Coated Calcium Alginate Beads as Oral Insulin Carrier. Molecular Pharmaceutics, 2018, 15, 3369-3382.	2.3	40
30	Accuracy of tablet splitting and liquid measurements: an examination of who, what and how. Journal of Pharmacy and Pharmacology, 2017, 69, 603-612.	1.2	29
31	Curcumin, Piperine, and Capsaicin: A Comparative Study of Spice-Mediated Inhibition of Human Cytochrome P450 Isozyme Activities. Drug Metabolism and Disposition, 2017, 45, 49-55.	1.7	42
32	Multifunctional nanoparticles for co-delivery of paclitaxel and carboplatin against ovarian cancer by inactivating the JMJD3-HER2 axis. Nanoscale, 2017, 9, 13142-13152.	2.8	46
33	Renal-targeted delivery of triptolide by entrapment in pegylated TRX-20-modified liposomes. International Journal of Nanomedicine, 2017, Volume 12, 5673-5686.	3.3	28
34	Nanomedicine-Mediated Therapies to Target Breast Cancer Stem Cells. Frontiers in Pharmacology, 2016, 7, 313.	1.6	64
35	Doseâ€Dependent Therapeutic Distinction between Active and Passive Targeting Revealed Using Transferrinâ€Coated PGMA Nanoparticles. Small, 2016, 12, 351-359.	<b>5.</b> 2	51
36	Colloidal Polymeric Platform for Facile Click-Assisted Ligand Functionalization and Receptor Targeting. ACS Omega, 2016, 1, 1114-1120.	1.6	4

#	Article	IF	CITATIONS
37	Paclitaxel-loaded phosphonated calixarene nanovesicles as a modular drug delivery platform. Scientific Reports, 2016, 6, 23489.	1.6	52
38	Shear induced carboplatin binding within the cavity of a phospholipid mimic for increased anticancer efficacy. Scientific Reports, 2015, 5, 10414.	1.6	30
39	Renal targeted delivery of triptolide by conjugation to the fragment peptide of human serum albumin. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 94, 363-371.	2.0	34
40	Characterization and biological properties of NanoCUR formulation and its effect on major human cytochrome P450 enzymes. International Journal of Pharmaceutics, 2015, 495, 194-203.	2.6	10
41	Development and validation of a LC/TOF MS method for the determination of carboplatin and paclitaxel in nanovesicles. Analytical and Bioanalytical Chemistry, 2014, 406, 2659-2667.	1.9	19
42	l-Carnitine ester of prednisolone: Pharmacokinetic and pharmacodynamic evaluation of a type I prodrug. International Journal of Pharmaceutics, 2014, 475, 123-129.	2.6	16
43	Application of multiple stepwise spinning disk processing for the synthesis of poly(methyl acrylates) coated chitosan–diclofenac sodium nanoparticles for colonic drug delivery. European Journal of Pharmaceutical Sciences, 2013, 50, 303-311.	1.9	31
44	RNA aptamers targeting cancer stem cell marker CD133. Cancer Letters, 2013, 330, 84-95.	3.2	157
45	Preparation and physicochemical characterization of a novel paclitaxel-loaded amphiphilic aminocalixarene nanoparticle platform for anticancer chemotherapy. Journal of Pharmacy and Pharmacology, 2012, 64, 1403-1411.	1.2	22
46	Cytotoxicity of monodispersed chitosan nanoparticles against the Caco-2 cells. Toxicology and Applied Pharmacology, 2012, 262, 273-282.	1.3	58
47	Chitin-Methacrylate: Preparation, Characterization and Hydrogel Formation. Materials, 2011, 4, 1728-1746.	1.3	28
48	Design, synthesis, characterization and in-vivo activity of a novel salmon calcitonin conjugate containing a novel PEC-lipid moiety. Journal of Pharmacy and Pharmacology, 2010, 62, 296-304.	1.2	6
49	Application of Plant Viruses as Nano Drug Delivery Systems. Pharmaceutical Research, 2010, 27, 2509-2513.	1.7	36
50	Uptake and cytotoxicity of chitosan nanoparticles in human liver cells. Toxicology and Applied Pharmacology, 2010, 249, 148-157.	1.3	122
51	Spinning Disc Processing Technology: Potential for Large-Scale Manufacture of Chitosan Nanoparticles. Journal of Pharmaceutical Sciences, 2010, 99, 4326-4336.	1.6	31
52	Wheat germ agglutinin-conjugated PLGA nanoparticles for enhanced intracellular delivery of paclitaxel to colon cancer cells. International Journal of Pharmaceutics, 2010, 400, 201-210.	2.6	72
53	Lipeo-sCT: A novel reversible lipidized salmon calcitonin derivative, its biophysical properties and hypocalcemic activity. European Journal of Pharmaceutical Sciences, 2009, 37, 151-159.	1.9	11
54	Synthesis, Characterization and In Vivo Activity of Salmon Calcitonin Coconjugated With Lipid and Polyethylene Glycol. Journal of Pharmaceutical Sciences, 2009, 98, 1438-1451.	1.6	11

#	Article	IF	Citations
55	Dietary regulation of P-gp function and expression. Expert Opinion on Drug Metabolism and Toxicology, 2009, 5, 789-801.	1.5	43
56	In vitro and in vivo evaluation of the effects of piperine on P-gp function and expression. Toxicology and Applied Pharmacology, 2008, 230, 283-289.	1.3	94
57	Comparison of Reversible and Nonreversible Aqueous-Soluble Lipidized Conjugates of Salmon Calcitonin. Molecular Pharmaceutics, 2008, 5, 610-621.	2.3	11
58	Effects of Spice Constituents on P-Glycoprotein-Mediated Transport and CYP3A4-Mediated Metabolism in Vitro. Drug Metabolism and Disposition, 2008, 36, 1283-1290.	1.7	82
59	Impact of Curcumin-Induced Changes in P-Glycoprotein and CYP3A Expression on the Pharmacokinetics of Peroral Celiprolol and Midazolam in Rats. Drug Metabolism and Disposition, 2007, 35, 110-115.	1.7	121
60	Folic Acid-Conjugated Protein Cages of a Plant Virus:Â A Novel Delivery Platform for Doxorubicin. Bioconjugate Chemistry, 2007, 18, 836-843.	1.8	192
61	Effects of citrus fruit juices on cytotoxicity and drug transport pathways of Caco-2 cell monolayers. International Journal of Pharmaceutics, 2006, 307, 42-50.	2.6	33
62	In vitro-reassembled plant virus-like particles for loading of polyacids. Journal of General Virology, 2006, 87, 2749-2754.	1.3	67
63	Aqueous-Soluble, Non-Reversible Lipid Conjugate of Salmon Calcitonin: Synthesis, Characterization and In Vivo Activity. Pharmaceutical Research, 2006, 24, 99-110.	1.7	31
64	Effects of capsaicin on P-gp function and expression in Caco-2 cells. Biochemical Pharmacology, 2006, 71, 1727-1734.	2.0	42
65	Pharmacological activity of peroral chitosan–insulin nanoparticles in diabetic rats. International Journal of Pharmaceutics, 2005, 293, 271-280.	2.6	211
66	Preparation and in vitro anticancer activity of wheat germ agglutinin (WGA)-conjugated PLGA nanoparticles loaded with paclitaxel and isopropyl myristate. Journal of Controlled Release, 2005, 107, 30-42.	4.8	113
67	Transfection efficiency of chitosan vectors: Effect of polymer molecular weight and degree of deacetylation. Journal of Controlled Release, 2005, 106, 391-406.	4.8	318
68	Paclitaxel-loaded PLGA nanoparticles: Potentiation of anticancer activity by surface conjugation with wheat germ agglutinin. Journal of Controlled Release, 2005, 108, 244-262.	4.8	136
69	Effect of Chitosan Salts and Molecular Weight on a Nanoparticulate Carrier for Therapeutic Protein. Pharmaceutical Development and Technology, 2005, 10, 189-196.	1.1	53
70	Effect of Chitosan Salts and Molecular Weight on a Nanoparticulate Carrier for Therapeutic Protein. Pharmaceutical Development and Technology, 2005, 10, 189-196.	1.1	6
71	Therapeutic Drugs that Behave as Mechanism-Based Inhibitors of Cytochrome P450 3A4. Current Drug Metabolism, 2004, 5, 415-442.	0.7	156
72	Characterization of chitosan acetate as a binder for sustained release tablets. Journal of Controlled Release, 2004, 99, 15-26.	4.8	137

#	Article	IF	Citations
73	Uptake and Cytotoxicity of Chitosan Molecules and Nanoparticles: Effects of Molecular Weight and Degree of Deacetylation. Pharmaceutical Research, 2004, 21, 344-353.	1.7	697
74	Hydroxyapatite–chitin materials as potential tissue engineered bone substitutes. Biomaterials, 2004, 25, 1049-1058.	5.7	141
75	Mechanistic study of the uptake of wheat germ agglutinin-conjugated PLGA nanoparticles by A549 cells. Journal of Pharmaceutical Sciences, 2004, 93, 20-28.	1.6	77
76	Flexible chitin films: structural studies. Carbohydrate Research, 2004, 339, 2701-2711.	1.1	55
77	Insulinâ€Loaded Calcium Pectinate Nanoparticles: Effects of Pectin Molecular Weight and Formulation pH. Drug Development and Industrial Pharmacy, 2004, 30, 359-367.	0.9	65
78	Herbal Modulation of Pâ€Glycoprotein. Drug Metabolism Reviews, 2004, 36, 57-104.	1.5	355
79	Uptake of Chitosan and Associated Insulin in Caco-2 Cell Monolayers: A Comparison Between Chitosan Molecules and Chitosan Nanoparticles. Pharmaceutical Research, 2003, 20, 1812-1819.	1.7	233
80	Modulation of digoxin transport across Caco-2 cell monolayers by citrus fruit juices: lime, lemon, grapefruit, and pummelo. Pharmaceutical Research, 2003, 20, 169-176.	1.7	42
81	Flexible chitin films as potential wound-dressing materials: Wound model studies. Journal of Biomedical Materials Research Part B, 2003, 66A, 224-232.	3.0	127
82	Implantable applications of chitin and chitosan. Biomaterials, 2003, 24, 2339-2349.	5.7	1,474
83	Ultrasonication of chitosan and chitosan nanoparticles. International Journal of Pharmaceutics, 2003, 265, 103-114.	2.6	185
84	Formulation pH modulates the interaction of insulin with chitosan nanoparticles. Journal of Pharmaceutical Sciences, 2002, 91, 1396-1404.	1.6	165
85	Chitosan-alginate PEC membrane as a wound dressing: Assessment of incisional wound healing. Journal of Biomedical Materials Research Part B, 2002, 63, 610-618.	3.0	266
86	Uptake of FITC-chitosan nanoparticles by A549 cells. Pharmaceutical Research, 2002, 19, 1488-1494.	1.7	353
87	Chitosan–alginate–CaCl2 system for membrane coat application. Journal of Pharmaceutical Sciences, 2001, 90, 1134-1142.	1.6	95
88	Preparation and characterization of chitin beads as a wound dressing precursor. Journal of Biomedical Materials Research Part B, 2001, 54, 59-68.	3.0	67
89	Chitosan-alginate films prepared with chitosans of different molecular weights. Journal of Biomedical Materials Research Part B, 2001, 58, 358-365.	3.0	155
90	Concurrent production of chitin from shrimp shells and fungi. Carbohydrate Research, 2001, 332, 305-316.	1.1	193

#	Article	IF	CITATIONS
91	PEC Films Prepared from Chitosan-Alginate Coacervates Chemical and Pharmaceutical Bulletin, 2000, 48, 941-946.	0.6	71
92	Caffeine and nicotinamide enhances the aqueous solubility of the antimalarial agent halofantrine. European Journal of Pharmaceutical Sciences, 2000, 10, 17-28.	1.9	48
93	Pharmacistâ€operated drug information centres in Singapore. Journal of Clinical Pharmacy and Therapeutics, 1999, 24, 33-42.	0.7	8
94	Effects of dry heat and saturated steam on the physical properties of chitosan., 1999, 48, 111-116.		85
95	Storage of partially deacetylated chitosan films. , 1999, 48, 881-888.		36
96	The Antimalarial Agent Halofantrine Perturbs Phosphatidylcholine and Phosphatidylethanolamine Bilayers: a Differential Scanning Calorimetric Study Chemical and Pharmaceutical Bulletin, 1999, 47, 732-737.	0.6	6
97	? Irradiation of chitosan. , 1998, 43, 282-290.		95
98	Stability of cefazolin sodium eye drops. Journal of Clinical Pharmacy and Therapeutics, 1998, 23, 41-47.	0.7	13
99	Effect of magnesium stearate on chitosan microspheres prepared by an emulsification-coacervation technique. Journal of Microencapsulation, 1998, 15, 319-333.	1.2	26
100	Propranolol Hydrochloride Binding in Calcium Alginate Beads. Drug Development and Industrial Pharmacy, 1997, 23, 973-980.	0.9	26
101	Chitosan Microspheres Prepared by Emulsification and Ionotropic Gelation. Drug Development and Industrial Pharmacy, 1997, 23, 981-985.	0.9	69
102	Stability of phenoxybenzamine hydrochloride in various vehicles. American Journal of Health-System Pharmacy, 1997, 54, 2073-2078.	0.5	2
103	Stability of admixtures of pethidine and metoclopramide in aqueous solution, 5% dextrose and 0.9% sodium chloride. Journal of Clinical Pharmacy and Therapeutics, 1997, 22, 339-345.	0.7	2
104	Stability of morphine sulphate in saline under simulated patient administration conditions. Journal of Clinical Pharmacy and Therapeutics, 1997, 22, 405-410.	0.7	5
105	A Differential Scanning Calorimetry Study of the Interaction of the Antimalarial Agent Halofanthrine with Dipalmitoyl Phosphatidyl Choline Bilayers Chemical and Pharmaceutical Bulletin, 1995, 43, 2226-2231.	0.6	15
106	Combined Effects of Heat Treatment and Plasticizers on Polyvinyl Alcohol Films. Drug Development and Industrial Pharmacy, 1995, 21, 369-373.	0.9	8
107	Heat Treatment of Chitosan Films. Drug Development and Industrial Pharmacy, 1995, 21, 839-846.	0.9	56
108	The Effect of Plasticizers on the Properties of Polyvinyl Alcohol Films. Drug Development and Industrial Pharmacy, 1994, 20, 1007-1020.	0.9	48

#	Article	IF	CITATION
109	Drug release from heat-treated polyvinyl alcohol films. Drug Development and Industrial Pharmacy, 1992, 18, 1895-1906.	0.9	25
110	THE ANTICHOLINESTERASE ACTIVITY OF MEFLOQUINE. Clinical and Experimental Pharmacology and Physiology, 1985, 12, 527-531.	0.9	26